Real life outcomes of patients aged =75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry.


Por: Salamero O, Martínez-Cuadrón D, Sobas M, Benavente C, Vives S, De la Serna J, Pérez-Encinas M, Escoda L, Gil C, Brunet S, Ramos F, Esteve J, Amigo M, Krsnik I, Manso F, Arias J, González-Campos J, Serrano J, Oleksiuk J, Barrios M, García-Boyero R, Novo A, Sanz MA, Montesinos P and PETHEMA and PALG Groups

Publicada: 1 nov 2019
Resumen:
Acute promyelocytic leukemia is infrequent among patients aged =75 years old, a population that is rarely eligible for clinical protocols. This study aims to analyze the treatment strategies and clinical outcomes of very old APL patients reported to the international PETHEMA registry. Between 1997 and 2017, among 2501 APL cases registered 120 were =75 years old. Treatment approaches were: AIDA regimen, 79 patients; ATRA alone, 23; 16, supportive care (SC) and 2, other strategies. Patients treated with AIDA were younger, had better ECOG and lower leukocytes. Complete remission (CR) was achieved in 65% of AIDA-group vs. 45% in the ATRA-group, being infections followed by bleeding the most frequent causes of induction death. Patients in CR after AIDA showed 3-year DFS of 73%. Our real-life series of very old APL patients provides a reference basis for future treatment strategies aiming to improve clinical outcomes in this challenging population.

Filiaciones:
Salamero O:
 UAB-Medicine Department, Hospital Universitario Vall d'Hebron, VHIO, Barcelona, Spain

Martínez-Cuadrón D:
 Hospital Universitari i Politecnic La Fe, valencia, Spain

 CIBERONC, Instituto Carlos III, Madrid, Spain

Sobas M:
 Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland

Benavente C:
 Hospital Clínico San Carlos, Madrid, Spain

Vives S:
 ICO-Hospital Universitari Germans Trias i Pujol, Jose Carreras Research Institute, Badalona, Spain

De la Serna J:
 Hospital 12 de Octubre, Madrid, Spain

Pérez-Encinas M:
 Hospital Clínico Universitario, Santiago de Compostela, Spain

Escoda L:
 Hospital Joan XXIII, Tarragona, Spain

:
 Hospital General de Alicante, Alicante, Spain

Brunet S:
 Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain

Ramos F:
 Hospital Universitario de León, Léon, Spain

Esteve J:
 Hospital Clinic, Barcelona, Spain

Amigo M:
 Hospital Morales Meseguer, Murcia, Spain

Krsnik I:
 Hospital Puerta del Hierro, Madrid, Spain

Manso F:
 Hospital General de Albacete, Albacete, Spain

Arias J:
 Hospital Universitario Lucus Augusti, Lugo, Spain

González-Campos J:
 Hospital Universitario Virgen del Rocío, Sevilla, Spain

Serrano J:
 Hospital Reina Sofía, Córdoba, Spain

Oleksiuk J:
 Medical University of Bialystok, Bialystok, Poland

Barrios M:
 Hospital Regional Universitario Carlos Haya, Málaga, Spain

García-Boyero R:
 Hospital General de Castellón, Castellón, Spain

Novo A:
 Hospital Universitari Son Espases, Palma, Spain

Sanz MA:
 Hospital Universitari i Politecnic La Fe, valencia, Spain

 CIBERONC, Instituto Carlos III, Madrid, Spain

Montesinos P:
 Hospital Universitari i Politecnic La Fe, valencia, Spain

 CIBERONC, Instituto Carlos III, Madrid, Spain
ISSN: 10428194





LEUKEMIA & LYMPHOMA
Editorial
TAYLOR & FRANCIS LTD, 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 60 Número: 11
Páginas: 2720-2732
WOS Id: 000503215900015
ID de PubMed: 31068052

MÉTRICAS